GlassScriptPhysician profile
Todd L Newman
NPI 1730398140
$73,099.43
in general payments reported to CMS, 2019-2025
32 companies · $33K in 2025
The $33K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,265 · 2022: $5,211 · 2023: $14K · 2024: $18K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $16K · Travel and Lodging: $4,448 · Consulting Fee: $4,135 · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,947.00 |
| Food and Beverage | $15,716.47 |
| Travel and Lodging | $4,447.71 |
| Consulting Fee | $4,135.00 |
| Education | $377.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20,553.02 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $19,818.35 | 2021-2025 | |
| Galderma Laboratories, L.P. | $12,720.97 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Incyte Corporation | $6,031.00 | 2022-2025 | Opzelura, Opzelura |
| Pfizer INC. | $2,891.97 | 2021-2025 | |
| Leo Pharma INC. | $1,903.85 | 2022-2025 | Adbry, Anzupgo |
| Abbvie INC. | $1,524.00 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,226.85 | 2022-2025 | |
| Dermavant Sciences, INC. | $768.51 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $768.18 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $753.25 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Journey Medical Corporation | $567.36 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $560.82 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $546.26 | 2022-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $541.33 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $506.81 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $352.37 | 2022-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $250.63 | 2021-2025 | Cabtreo, Jublia, Arazlo |
| Mayne Pharma Commercial LLC | $210.84 | 2022-2025 | |
| Botanix Sb INC | $163.93 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Sebela Pharmaceuticals INC. | $54.82 | 2021-2023 | Naftin |
| Organon LLC | $49.62 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.22 | 2022-2025 | Spevigo |
| Genentech USA, INC. | $37.62 | 2023 | Xolair |
| Verrica Pharmaceuticals INC. | $32.56 | 2024 | Ycanth |
| Epi Health, LLC | $28.73 | 2022 | |
| Fidia Pharma USA INC. | $24.71 | 2025 | |
| Ani Pharmaceuticals, INC. | $18.77 | 2025 | Veregen |
| Almirall LLC | $16.67 | 2025 | Seysara |
| Kyowa Kirin, INC. | $14.41 | 2023 | Poteligeo |
| Nabriva Therapeutics, Plc | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.